What does Preamble of Prescription Pricing for the People Act of 2025 do?

This bill requires the Federal Trade Commission (FTC) to study the role of intermediaries in the pharmaceutical supply chain. The FTC is directed to provide Congress with policy recommendations based on its study.

What does SHORT TITLE. of Prescription Pricing for the People Act of 2025 do?

This bill is formally titled the Prescription Pricing for the People Act of 2025.

What does DEFINITIONS. of Prescription Pricing for the People Act of 2025 do?

This section defines terms used within the Act. “Appropriate committees of Congress” are defined as the Committee on the Judiciary of the Senate and the Committee on the Judiciary of the House of Representatives. “Commission” is defined as the Federal Trade Commission.

What does STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER of Prescription Pricing for the People Act of 2025 do?

This section directs the Commission to submit a report to Congress regarding pharmaceutical supply chain intermediaries and merger activity. The report must address whether pharmacy benefit managers (PBMs) engage in practices such as charging payers higher prices than pharmacy reimbursements, steering patients to affiliated pharmacies, or using proprietary pharmacy data for competitive advantage. The report should also analyze trends in healthcare supply chain competition, particularly concerning intermediaries. It requires an assessment of how companies and payers evaluate contracts with intermediaries and whether more information should be available to consumers. The Commission must identify legal or regulatory obstacles hindering antitrust and consumer protection enforcement in the pharmaceutical supply chain. The report must include observations from a 2017 roundtable on prescription drug competition and outline planned actions, research, or enforcement efforts. Finally, the report should offer policy or legislative recommendations to improve transparency, prevent anticompetitive behavior, and ensure consumer benefits from mergers and consolidations.

What does REPORT. of Prescription Pricing for the People Act of 2025 do?

This section requires the Commission to submit a report to Congress. The report must include the number and nature of complaints received regarding alleged anticompetitive conduct by sole-source drug manufacturers. The report must also assess the Commission's ability to bring enforcement actions against such manufacturers. Finally, the report must contain policy or legislative recommendations to strengthen enforcement actions related to anticompetitive behavior.

Back to bills

Prescription Pricing for the People Act of 2025

Last updated: 4/10/2025 · Introduced: 2/11/2025

Author: Chuck Grassley (R-IA)

TL;DR (AI)

The Federal Trade Commission (FTC) must study pharmaceutical supply chain intermediaries, including pharmacy benefit managers (PBMs), to assess anticompetitive practices and trends.
The FTC is required to report to Congress on complaints against sole-source drug manufacturers and its ability to enforce antitrust laws in that context.
The bill directs the FTC to provide policy and legislative recommendations to Congress for improving transparency and preventing anticompetitive behavior within the pharmaceutical supply chain.

119th Congressin committeeOfficial page

Verified Votes

No verified votes yet.

Community Votes

No community votes yet. Be the first!

Voting as guest · Sign in for verified votes

Other Sections

Includes provisions on preamble, short title., and 3 more.

5 sections

Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.

Read official text

Want the full experience?

Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.

Create Free Account